
Opinion|Videos|November 29, 2023
Momelotinib in MF: Data from the SIMPLIFY-1 Trial
Author(s)Anthony Hunter, MD
The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Panel Votes 10-3 In Favor of RP1 Plus Nivolumab for Advanced Melanoma
3
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer
4
July 2026 in Oncology: A Look Back at FDA Approvals and Decisions
5


































